Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Income from Continuing Operations data on file, last reported at 164494000.0 in Q2 2026.

• Quarterly Income from Continuing Operations rose 327.74% year-over-year to 164494000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 774711000.0 (up 371.06% YoY) and the FY2025 annual result came in at 313747000.0, up 212.79% from the prior year.
• Income from Continuing Operations declined to 164494000.0 in Q2 2026, from 205991000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 292683000.0 in Q3 2025 to a low of 405920000.0 in Q3 2022.
• A 5-year average of 64740166.67 and a median of 77995500.0 in 2024 frame the typical range for Income from Continuing Operations.
• Annual changes were most pronounced in 2025 — Income from Continuing Operations sank 327.66% — and 2026, when it soared 1228.66%.
• Tracing ALNY's Income from Continuing Operations over 5 years: stood at 207493000.0 in 2022, then soared by 33.55% to 137870000.0 in 2023, then soared by 39.24% to 83763000.0 in 2024, then jumped by 233.17% to 111543000.0 in 2025, then surged by 47.47% to 164494000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 164494000.0 (Q2 2026), 205991000.0 (Q1 2026), and 111543000.0 (Q4 2025), per Business Quant data.